

Macular Degeneration Guideline Committee – development

Date: 13/01/2016

Location: NICE offices, London

Minutes: Final

Committee members present:		
Waqaar Shah (Chair)		Present for all items
Katy Barnard (KB)		Present for all items
Cathie Burke (CB)		Joined during item 1
Jennifer Evans (JE)		Present for all items
Alexander Foss (AF)		Present for all items
Mary Freeman (MF)		Present for all items
Carol McCletchie (CM)		Present for all items
Ellen Rule (ER)		Present for all items
Mary-Ann Sherratt (MAS)		Present for all items
Cathy Yelf (CY)		Present for all items

In attendance:		
Stephen Duffield (SD)	ICG – Technical Analyst	Present for all items
Chris Gibbons (CG)	ICG – Technical Analyst (HE)	Present for all items
Caroline Keir (CK)	NICE – Guideline Commissioning Manager	Present up to item 2
Vonda Murray (VM)	ICG – Project Manager	Present for all items
Dave Nicholls (DN)	NICE – Information Specialist	Present for all items
Gabriel Rogers (GR)	ICG – Technical Advisor	Present for all items

Macular Degeneration Guideline Committee 4 minutes

	(HE)	
--	------	--

Observers:

Paulo Dias	NICE – Medical student on placement
Rosa Domingues	NICE – Technical Analyst
Judith Hughes	PhD student

Apologies:

Andy Charley (AC)	Committee member
Anne Louise Clayton (A-LC)	NICE – Medicine Senior Editor
Sue Ellerby	ICG – Clinical Advisor
Elizabeth Wick	Committee member

1. Introductions, apologies, minutes, DOI and objectives for the meeting

The Chair welcomed the Committee members, attendees and observers to the third meeting on age-related macular degeneration (AMD). The Committee members, attendees and observers introduced themselves.

Apologies were noted, as recorded above.

The Chair confirmed having reviewed the historical declaration of interests table stated that there was no conflict of interest. He asked each committee member to declare any new conflicts since the previous meeting. There were no new conflicts of interest declared, with the following exception:

Name	Declarations of Interest, date declared	Type of interest	Decision taken
Alexander Foss (AF)	Paper 'Patient views on macular degeneration', has been accepted for publication 13.01.16	Personal, non-financial, specific interest	Declare and participate

It was agreed that all committee members were eligible to attend the committee meeting and contribute to the discussions and drafting of any recommendations.

The minutes were reviewed from GDG 13; 25/11/2015, it was highlighted for item 3, that the word ration should be changed to ratio. The minutes were otherwise agreed to be an accurate record.

Action – VM to alter minutes, item 3 alter word ration to ratio

The Chair provided a brief overview and objectives of the day highlighting the information that would be discussed.

2. Overview of AMD

AF presented an overview of AMD

3. Explanation of diagnostic outcomes

Presentation of RQ1, signs and symptoms of AMD

Presentation of RQ6, classification systems for AMD

RQ6, classification systems for AMD

Based on the agreed review protocol 10 studies were included in the evidence base. The Committee discussed the evidence and agreed which classification systems would be adopted.

Action – SD to develop synergy between the committee’s preferred classification systems.

Action – VM to add to agenda for the next meeting

RQ1, signs and symptoms of AMD

Based on the agreed review protocol 1 study was included in the evidence base. The committee discussed the evidence presented and a draft recommendation was made by the committee.

4. Review protocols

Protocols for the following review questions were agreed:

RQ4 What tools are useful for triage, diagnosis, informing treatment and determining management in people with suspected AMD?

RQ23 What strategies and tools are useful for monitoring and self-monitoring for people with AMD?

RQ3 What information do people with suspected or confirmed AMD and their family members or carers find useful, and in what format (for example written or oral), and when?

8. Next steps

The Chair thanked the committee for their time and contribution to the meeting. The venue, date and time of the next meeting was confirmed.

VM asked committee members that require accommodation to be arranged by NICE, to make this request at least three weeks before the meeting.

Date of next meeting: Wednesday 24 February 2016

Location of next meeting: NICE offices, London